Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications

Oliveira, Gustavo Laine Araújo de; Júnior, Augusto Afonso Guerra; Godman, Brian; Acúrcio, Francisco de Assis

doi:10.1080/14737167.2017.1292852

Cited by 13 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients treated with IGla in our study did not have adequate HbA1c control. Our findings are similar to those found by Marra et al (2017) (72) and Souza el al (2015) (43), with more than 60% of patients with poor control of HbA1c which again can be different from other published studies. Two other Brazilian studies (73,74) also found poor glycemic control in DM patients, which needs to be addressed going forward.…”

Section: Discussionsupporting

confidence: 86%

“…Type 1 Diabetes Mellitus (T1DM) is a chronic, costly disease, both for people living with T1DM and for governments and society (1,2). The economic burden of T1DM is largely due to the costs of medicines and the complications of diabetes (3,4), with the different insulins differing in terms of their pharmacokinetic parameters as well as costs (5).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications

et al. 2022

Self Cite

View full text Add to dashboard Cite

This article describes a cross-sectional study involving 401 adults with type 1 diabetes treated with insulin glargine in Minas Gerais, Brazil. Health-related quality of life was assessed, and worse scores were found to be associated with a low level of education, self-perceived health reported as poor/very poor, being bedridden and not physically exercised, having seen a doctor more than four times in the past year, and having reported comorbidities and episodes of hypoglycemia.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…• HTA can contribute to such analyses [129]. However, different methods may be needed to fully incorporate the benefits and value of new medicines for cancer into future pricing considerations given affordability constraints that exist within countries, especially LMICs.…”

Section: Buyers (Including Health Authorities and Patients)mentioning

confidence: 99%

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Godman

Hill

Simoens

et al. 2021

Expert Review of Pharmacoeconomics & Outcomes Research

Self Cite

View full text Add to dashboard Cite

Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.

show abstract

“…Diabetes mellitus (DM) is a chronic and complex disease that requires continuous medical care. DM can be subdivided into several etiological types, with Type 1 DM (T1DM) and Type 2 DM (T2DM) being the most prevalent [ 1 ]. T1DM is characterized by the destruction of the islets of Langerhans and insulin-secreting β1 cells in the pancreas mediated by the immune response, and its treatment is based on the replacement of deficient or non-existent insulin [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications

Almeida

Silva

Acúrcio

et al. 2018

Patient

Self Cite

View full text Add to dashboard Cite

IntroductionInsulin analog glargine (GLA) has been available as one of the therapeutic options for patients with type 1 diabetes mellitus to enhance glycemic control. Studies have shown that a decrease in the frequency of hypoglycemic episodes improves the quality of life (QoL) of diabetic patients. However, there are appreciable acquisition cost differences between different insulins. Consequently, there is a need to assess their impact on QoL to provide future guidance to health authorities.MethodA systematic review of multiple databases including Medline, LILACS, Cochrane, and EMBASE databases with several combinations of agreed terms involving randomized controlled trials and cohorts, as well as manual searches and gray literature, was undertaken. The primary outcome measure was a change in QoL. The quality of the studies and the risk of bias was also assessed.ResultsEight studies were eventually included in the systematic review out of 634 publications. Eight different QoL instruments were used (two generic, two mixed, and four specific), in which the Diabetes Treatment Satisfaction Questionnaire (DTSQ) was the most used. The systematic review did not consistently show any significant difference overall in QoL scores, whether as part of subsets or combined into a single score, with the use of GLA versus neutral protamine Hagedorn (NPH) insulin. Only in patient satisfaction measured by DTSQ was a better result consistently seen with GLA versus NPH insulin, but not using the Well-being Inquiry for Diabetics (WED) scale. However, none of the cohort studies scored a maximum on the Newcastle–Ottawa scale for quality, and they generally were of moderate quality with bias in the studies.ConclusionThere was no consistent difference in QoL or patient-reported outcomes when the findings from the eight studies were collated. In view of this, we believe the current price differential between GLA and NPH insulin in Brazil cannot be justified by these findings.Electronic supplementary materialThe online version of this article (10.1007/s40271-017-0291-3) contains supplementary material, which is available to authorized users.

show abstract

Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications

Cited by 13 publications

References 44 publications

A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications

A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications

Contact Info

Product

Resources

About